再论肝癌TACE与HAIC的联合临床应用  

A further discussion on the clinical application of TACE and HAIC for hepatocellular carcinoma

作　　者：葛乃建 杨业发 GE Naijian;YANG Yefa(Department of Interventional Radiology,Shanghai Eastern Hepatobiliary Surgery Hospital,Third Affiliated Hospital of Naval Medical University,Shanghai 200438,China)

机构地区：[1]海军军医大学第三附属医院(上海东方肝胆外科医院)放射介入科,上海2004383

出　　处：《介入放射学杂志》2025年第2期129-133,共5页Journal of Interventional Radiology

基　　金：国家自然科学基金面上项目(31971249,52372277);东方肝胆外科医院领英人才项目。

摘　　要：经动脉化疗栓塞术(TACE)是公认的肝癌非手术切除的首选治疗方式,而肝动脉灌注化疗术(hepatic artery infusion chemotherapy,HAIC)是另一种有效的介入方法。两者用于治疗肝癌的研究众多,也引起了医学界广泛的争论。将肝癌HAIC与TACE的合理联用定义为灌注TACE(iTACE,infusion transarterial chemoembolization)。该文从iTACE的概念、应用方法、适应证和禁忌证、疗效与不良反应、联合靶向免疫等方面进行介绍,期望有助于临床的推广应用。Transarterial chemoembolization(TACE)has been well recognized as the preferred treatment for non-surgical resection of hepatocellular carcinoma(HCC),while hepatic arterial infusion chemotherapy(HAIC)is another effective interventional method.Many studies on TACE and HAIC treatment for HCC have been reported,which has aroused widespread debate in the medical field.Reasonable combination use of HAIC and TACE is defined as infusion transarterial chemoembolization(iTACE).This paper aims to make a comprehensive introduction about iTACE,focusing on its concept,applied method,indications and contraindications,efficacy and adverse reactions,combination with targeted immunotherapy,etc.It is expected that this paper will provide useful reference for the promotion and application of iTACE in clinical practice.

关 键 词：肝动脉灌注化疗 经动脉化疗栓塞术 肝细胞癌 肝动脉灌注化疗与经动脉化疗栓塞联用 

分 类 号：R735.7[医药卫生—肿瘤]